Results 121 to 130 of about 44,319 (309)

Galectin-1 in myelin repair [PDF]

, 2016
Galectin-1 (Gal-1) is a member of a highly conserved family of animal lectins which binds to the common disaccharide [Galβ(1-4)-GlcNAc] on both N- and O-glycans decorating cell surface glycoconjugates.
Pasquini, Laura Andrea, Rinaldi, Mariana, Thomas, Laura   +2 more
core   +1 more source

Mapping Molecular Pathways of Multiple Sclerosis: A Gene Prioritization and Network Analysis of White Matter Pathology Transcriptomics

Annals of Neurology, EarlyView.
Objectives Rapid advances in transcriptomics have driven efforts to identify deregulated pathways in multiple sclerosis (MS) tissues, though many detected differentially expressed genes are likely false positives, with only a small fraction reflecting actual pathological events. Robust, integrative methods are essential for accurately understanding the
Gianmarco Abbadessa, Ai Nagano, Simon Hametner, Owain Howell, David Owen, Artemis Papadaki, Prashant Srivastava, Simona Bonavita, Roberta Magliozzi, Richard Reynolds, Mie Rizig, Richard Nicholas   +11 more
wiley   +1 more source

Bypassing damaged nervous tissue [PDF]

arXiv, 2016
It is shown the principal possibility of bypassing damaged demyelinated portions of the nervous tissue, thereby restoring its normal function for the passage of action potentials.
arxiv   +1 more source

Microarray screening of Guillain-Barré syndrome sera for antibodies to glycolipid complexes [PDF]

, 2016
Objective: To characterize the patterns of autoantibodies to glycolipid complexes in a large cohort of Guillain-Barré syndrome (GBS) and control samples collected in Bangladesh using a newly developed microarray technique.
Endtz, Hubert P., Halstead, Susan K., Islam, Mohammad B., Islam, Zhahirul, Jacobs, Bart C., Jahan, Israt, Kalna, Gabriela, Mohammad, Quazi D., Willison, Hugh J.   +8 more
core   +4 more sources

Neuropathological Evidence of Reduced Amyloid Beta and Neurofibrillary Tangles in Multiple Sclerosis Cortex

Annals of Neurology, EarlyView.
Multiple sclerosis (MS) and Alzheimer's disease are neurodegenerative diseases with age‐related disability accumulation. In MS, inflammation spans decades, whereas AD is characterized by Aβ plaques and neurofibrillary tangles (NFT). Few studies explore accumulation of amyloids in MS.
J. Pansieri, M. Pisa, S. Yee, A. Gutnikova, E. Ridgeon, R. Hickman, J.I. Spencer, M.M. Esiri, G.C. DeLuca   +8 more
wiley   +1 more source

Multivariate MR Biomarkers Better Predict Cognitive Dysfunction in Mouse Models of Alzheimers Disease [PDF]

arXiv, 2018
To understand multifactorial conditions such as Alzheimers disease (AD) we need brain signatures that predict the impact of multiple pathologies and their interactions. To help uncover the relationships between brain circuits and cognitive markers we have used mouse models that represent, at least in part, the complex interactions altered in AD.
arxiv  

Neurological complications of immune checkpoint inhibitors: what happens when you \u27take the brakes off\u27 the immune system. [PDF]

, 2018
Patients with advanced malignancies treated with immune checkpoint inhibitors are at increased risk for developing immune-related neurological complications.
Dalakas, Marinos
core   +1 more source

Optic neuritis in various demyelinating diseases

Неврология, нейропсихиатрия, психосоматика
The discovery of antibodies against aquaporin-4 (AQP4) and against myelinoligodendrocyte glycoprotein (MOG) confirmed the existence of two disease entities distinct from multiple sclerosis (MS) — neuromyelitis optica spectrum disorders (NMOSD) and ...
A. K. Kalashnikova, D. D. Eliseeva, N. A. Andreeva, N. V. Zhorzholadze, I. A. Ronzina, R. Ts. Bembeeva, N. N. Venediktova, M. R. Kalganova, N. L. Sheremet   +8 more
doaj   +1 more source

Obinutuzumab, a potent anti-B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy. [PDF]

, 2018
Anti-MAG demyelinating neuropathy is difficult to treat. All immunotherapies have failed except for rituximab, a chimeric B-cell–depleting monoclonal antibody against CD20, that helps up to 40% of patients based on 2 controlled and several uncontrolled ...
Dalakas, Marinos C., Martinez-Outshoorn, Ubaldo E., Rakocevic, Goran   +2 more
core   +1 more source

Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. [PDF]

, 2018
OBJECTIVE: We characterised the clinical course, treatment and outcomes in 59 patients with relapsing myelin oligodendrocyte glycoprotein (MOG) antibody-associated demyelination.
Australasian and New Zealand MOG Study Group Andrews, P, Barnett, Mh, Barton, J, Brilot, F, Broadley, S, Burrow, J, Butzkueven, H, Cairns, A, Calvert, S, Caruana, P, Chelakkadan, S, Clark, D, Dale, Rc, Fraser, C, Freeman, J, Fung, Vsc, Gill, D, Grattan-Smith, P, Gupta, S, Hardy, T, Henderson, Apd, Kothur, K, Lechner-Scott, J, Ling, S, Lopez, J, Malone, S, Marriott, M, Merheb, V, Mohammad, S, Nguyen, Tk, Nosadini, M, O'grady, G, Orr, C, Ouvrier, R, Parratt, J, Patrick, E, Pilli, D, Ramanathan, S, Reddel, Sw, Riminton, D, Riney, K, Rodriguez-Casero, V, Ryan, M, Scheffer, I, Shah, U, Shuey, N, Spooner, C, Subramanian, G, Tantsis, E, Tea, F, Thomas, T, Thompson, J, Troedson, C, Vucic, S, Ware, T, Webster, R, White, Ob, Yiannikas, C, Yiu, E, Zou, A.   +59 more
core   +1 more source